China Medical System Signs License Agreement With Biocodex

Bioflor (Saccharomyces boulardii) is a probiotic antidiarrheal product mainly used in the prevention and treatment of diarrhea, a common gastroentrologic disorder found in adults and children.

Under the agreement, the company has committed to purchase a minimum quantity of Bioflor from Biocodex during the next five years.

Lam Kong, CEO of CMS, said: “We are pleased to be working with Biocodex, our first French business partner, and with the addition of Bioflor to our portfolio. This agreement demonstrates our commitment to execute our growth strategy, which is to in-license on an exclusive basis high quality products and further expand our source of revenue.”

Nicolas Coudurier, international director of Biocodex, said: “Biocodex is extremely proud of this agreement with CMS. China represents one of the top priorities in Biocodex’s international development. CMS and Biocodex share the same value creation strategy, and CMS through its professionalism, high motivation and strong sales network proves to be the best option to grow our product Bioflor, being ‘the Number One probiotic drug worldwide’, in China.”